Mei-hung Pan (Taipei)
P-038 (138)
Predicting risk of hepatocellular carcinoma of patients with chronic hepatitis B using serum levels of hepatitis B virus DNA splicing
Yi-Chung Hsieh (Taoyuan)
0-017 (194)
Hepatitis B core-related antigen is a predictive factor for non-B, non-C hepatocellular carcinoma
Kuo-Chin Chang (Kaohsiung)
P-148 (129)
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than chronic hepatitis C in cirrhotic patients after effective antiviral therapies: The difference of common risk factors
Jia-Horng Kao (Taipei)
O-008 (141)
Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in Chronic Hepatitis B (CHB) Patients from East Asia
Ming-lung Yu (Kaohsiung)
O-013 (33)
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for the treatment of HCV genotype 1b infection without baseline NS5A resistance-associated variants (DARING)-Final report